Product Information
KISQALI 400 MG DAILY DOSE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $346.9469 per EA under NDC 00078086742. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Mar 13, 2017.
Strength
200 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078086742
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/22/2026
Active Ingredients
RIBOCICLIB SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA209092FDA Approved
3/13/2017
On Market Since
3/13/2017
Pharmacological Classes
Price Statistics
The NADAC for KISQALI 400 MG DAILY DOSE has been published 42 times since Dec 17, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $346.9469 per EA |
|---|---|
| All-time high | $347.4053 (Apr 15, 2026) |
| All-time low | $346.9384 (Apr 22, 2026) |
| 52-week high | $347.4053 |
| 52-week low | $346.9384 |
| Median price | $346.9469 |
| Average price | $347.1425 |
| Largest weekly change | -0.1% (Apr 22, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ribociclib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KISQALI 400 MG DAILY DOSE?
The current National Average Drug Acquisition Cost (NADAC) for KISQALI 400 MG DAILY DOSE, manufactured by Novartis Pharmaceuticals Corporation, is $346.9469 per EA (NDC 00078086742), effective Sep 30, 2026.
How has the price of KISQALI 400 MG DAILY DOSE changed over time?
Over the history we have for it, the NADAC for KISQALI 400 MG DAILY DOSE has held within roughly two percent of its current level. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for KISQALI 400 MG DAILY DOSE?
Since Dec 17, 2025, the NADAC for KISQALI 400 MG DAILY DOSE has ranged from a low of $346.9384 (Apr 22, 2026) to a high of $347.4053 (Apr 15, 2026), with a median of $346.9469 per EA.
Are there cheaper alternatives to KISQALI 400 MG DAILY DOSE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KISQALI 600 MG DAILY DOSE, is $289.7167 per EA — about 16% below KISQALI 400 MG DAILY DOSE.
Who manufactures KISQALI 400 MG DAILY DOSE?
KISQALI 400 MG DAILY DOSE (NDC 00078086742) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.